MISSION VIEJO, Calif.--(BUSINESS WIRE)--Aeolus Pharmaceuticals, Inc. (OTC Bulletin Board:AOLS) announced today the initiation of the first of a series of studies of AEOL 10150 as a countermeasure to mustard gas exposure. The studies, funded by the National Institutes for Health’s CounterACT program, have been designed to test the efficacy of AEOL 10150 as a treatment for damage to the skin, lungs and eyes due to exposure to sulfur mustard gas and to examine potential effective doses, duration of delivery and the window of opportunity for treatment after exposure.
